Supplementary data_310718 from Synergistic Interaction of <i>HOXB13</i> and <i>CIP2A</i> Predisposes to Aggressive Prostate Cancer

Supplementary Table 1. Clinical characteristics of Finnish prostate cancer patients Supplementary Table 2. Tumour Stage Group (TSG) definitions Supplementary Table 3. Follow-up characteristics used in survival analyses of Finnish prostate cancer patients Supplementary Table 4. Primer sequences used in quantitative RT-PCR reactions Supplementary Table 5. Assessment of PrCa risk due to the combination of HOXB13 T and CIP2A T in dual carriers relative to the risk in non-carriers Supplementary Table 6 Time-to-PrCa event of HOXB13 rs138213197 and CIP2A rs2278911 Supplementary Table 7 Association of HOXB13 G84E and CIP2A R229Q carrier status and clinical features of prostate cancer subgroups Supplementary Table 8. Association of HOXB13 and CIP2A carrier status and combined modality stage of prostate cancer patients according to ERSPC Supplementary Table 9. P-values for Figure1, Figure 2 and Supplementary figure 2. Supplementary figure 1. Higher mRNA expression pattern of HOXB13-CIP2A correlated with increased risk of prostate cancer biochemical recurrence. Supplementary figure 2. Effects of HOXB13 G84E and CIP2A R229Q variants on prostate cell migration. Supplementary figure 3. ChIP-qPCR in VCaP cell line Supplementary figure 4. Overexpression of HOXB13 G84E and CIP2A R229Q variants promotes cell proliferation.